Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 81 to 90 of 400 total matches.
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
.
The Medical Letter ® Vol. 65 (1675) May 1, 2023 Kloxxado opioid abuse naltrexone buprenorphine methadone ...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction
In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
.
The Medical Letter ® Vol. 67 (1726) April 14, 2025 Alzheimer's disease Leqembi lecanemab ...
The amyloid beta-directed monoclonal antibody
lecanemab-irmb (Leqembi – Eisai/Biogen) has now
been approved by the FDA for once-monthly use for
treatment of Alzheimer's disease (AD) in patients with
mild cognitive impairment (MCI) or mild dementia. It
was previously approved only for administration once
every 2 weeks. Now, lecanemab can be given every
4 weeks after an 18-month initiation phase of
biweekly administration.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):64 doi:10.58347/tml.2025.1726f | Show Introduction Hide Introduction
Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
telangiectasia type 2. Invest Ophthalmol Vis Sci 2023; 64:21.
The Medical Letter ® Vol. 67 Published online ...
Revakinagene taroretcel-lwey (Encelto – Neurotech),
an intravitreal allogeneic cell-based gene therapy, has
been approved by the FDA for treatment of idiopathic
macular telangiectasia type 2 in adults. It is the first
treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e74 doi:10.58347/tml.2025.1727f | Show Introduction Hide Introduction
In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
dose without having to split a
higher-strength tablet.
The Medical Letter ® Vol. 67 (1733) July 21 ...
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-, and 50-mg
tablets (Thalitone, and generics) and in fixed-dose
combinations with azilsartan medoxomil (Edarbyclor)
and atenolol (Tenoretic, and generics).
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118 doi:10.58347/tml.2025.1733e | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
Expanded Table: Some Vaccines for Adults online
The Medical Letter ® Vol. 64 (1661) October 17, 2022
162 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
of falls.
The Medical Letter ® Vol. 65 (1667) January 9, 2023
2
Benzodiazepine receptor agonists ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
The Medical Letter ® Vol. 65 (1674) April 17, 2023
58
Table 1. Empiric Treatment of Some Outpatient ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
creatinine
clearance, have been reported with long-term use of
The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
prohibited.
For further information call: 800-211-2769
The Medical Letter ® Vol. 66 (1717) December 9, 2024 ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
by methotrexate.
The Medical Letter ® Vol. 63 (1637) November 15, 2021
Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.